MedTrace Logo

Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome

NCT00429364 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 608

Last updated 2025-03-07

Study results available
· View outcomes & findings →

Summary

Marfan syndrome is a hereditary connective tissue disorder. Many individuals with this condition die because of the associated heart and blood vessel abnormalities. This study will compare the effectiveness of two medications, losartan and atenolol, at slowing aortic root enlargement in individuals with Marfan syndrome.

Conditions

  • Marfan Syndrome

Interventions

DRUG

Losartan Potassium

Losartan .3 - 1.4 mg/kg

DRUG

Atenolol

Atenolol .5 - 4 mg/kg

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • FDA Office of Orphan Products Development

    collaborator FED

  • National Marfan Foundation

    collaborator UNKNOWN

  • Carelon Research

    lead OTHER

Principal Investigators

  • Ron Lacro, MD · Boston Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • United States
  • Belgium
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00429364 on ClinicalTrials.gov